• Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Mar 2, 2023
Discovery & Translation

Merck’s HIV reservoir-reducing compounds; plus an anti-IL-8 mAb for endometriosis and more

BioCentury's roundup of translational news
Read More
BioCentury | Dec 10, 2020
Product Development

Second clinical readout for Evelo oral microbe-based therapy shows reduced severity in atopic dermatitis

Evelo’s Phase Ib readout in atopic dermatitis strengthens the case for its platform of oral microbiome-derived, gut-restricted therapies to modulate systemic immune activity. Evelo Biosciences
Read More
BioCentury | Aug 11, 2020
Product Development

Remdesivir heads for FDA review as Gilead continues to build manufacturing pipeline 

Plus data from Omeros, PTC and a call to make mAbs accessible
Read More
BioCentury | Oct 25, 2019
Product Development

Lykera takes aim at aggressive cancers by targeting pre-metastatic niche

Lykera's mAbs target S100 proteins implicated in driving cancer metastases
Read More
BioCentury | Oct 24, 2019
Preclinical News

Oct. 24 Preclinical Quick Takes: anti-neuraminidase human antibodies for broad flu protection; plus Ionis-Baylor, Merck and more

Read More
BioCentury | May 15, 2018
Distillery Therapeutics

Autoimmune disease

Read More
BioCentury | May 8, 2017
Distillery Therapeutics

Dermatology

Read More
BioCentury | Apr 21, 2017
Product R&D

Making marks at AACR

Reading biomarker signals at AACR 2017
Read More
BioCentury | Jan 27, 2017
Company News

SATT Sud-Est, Immune Pharmaceuticals deal

Read More
BioCentury | Sep 15, 2016
Distillery Therapeutics

Therapeutics: Mammalian target of rapamycin (mTOR; FRAP; RAFT1); interleukin-8 (IL-8; CXCL8)

Read More
Items per page:
1 - 10 of 30
Help Center
Username
Request Training
Submit Data Correction
Ask a Question
Elevio by Dixa